


R&D Pipeline



antibody



protein



small molecule

© New Molecular Entity

Updated since Dec. 31, 2020

Updated since Dec. 31, 2021

Nephrology

As of Mar. 31, 2021

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	CN Asia						[Mitsubishi Tanabe Pharma] product name in Japan: Orkedia
©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	JP						[Reata]
		Autosomal Dominant Polycystic Kidney Disease	JP						
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	JP						[In-House] product name in Japan: Acoalan
KHK7791 Tenapanor Oral	NHE3 Inhibitor	Hyperphosphatemia Under Maintenance Dialysis	JP						[Ardelyx]

Oncology

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	AU						[In-House] POTELLIGENT® product name in Japan, U.S. and Europe: Poteligeo
			CH SA KR						
			CA KW						
©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	JP						[Syndax]
KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony- Stimulating Factor	Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Allogeneic Blood Stem Cell Transplantation	JP						[Kirin-Amgen] product name in Japan: G-Lasta
		Automated Injection Device for Decreasing the Incidence of Febrile Neutropenia in Patients Receiving Cancer Chemotherapy	JP						
©KHK2455 Oral	IDO1 Inhibitor	Solid Tumor	NA						[In-House] Combination with KW-0761
		Urothelial carcinoma	NA						[In-House] Combination with avelumab
			EU						
©ME-401 Zandelisib Oral	PI3Kδ Inhibitor	Indolent B-cell Non-Hodgkin's Lymphoma	JP						[MEI Pharma]
		B-cell malignancies	NA						
		Follicular Lymphoma	NA EU Asia Oceania						

Immunology/Allergy

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Systemic Sclerosis	JP						[Kirin-Amgen] product name in Japan: Lumicef
		Palmoplantar Pustulosis	JP						
©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Atopic Dermatitis	JP NA EU						[In-House] POTELLIGENT® Human Antibody-Producing Technology
©ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in de novo kidney transplant recipients	NA						[In-House] Human Antibody-Producing Technology Jointly Developed with Astellas

R&D Pipeline

antibody
 protein
 small molecule

© New Molecular Entity

Updated since Dec. 31, 2020

Updated since Dec. 31, 2020

Central Nervous System

As of Mar. 31, 2021

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	EU						[In-House] product name in Japan: Nourias, product name in U.S.: Nouriaz
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	JP						[In-House] POTELLIGENT® product name in Japan, U.S. and Europe: Poteligeo
©KW-6356 Oral	Adenosine A _{2A} Receptor Antagonist/Inverse Agonist	Parkinson's Disease	JP						[In-House]
©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	JP EU						[Immunas Pharma]

Other

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	CN BH						[In-House] Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU product name in Japan, U.S. and Europe: Crisvita
			AU SA SG						
			TL MY						
		Tumor Induced Osteomalacia (TIO)	CN						
			EU						
			CA						
AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	Asia						[Kirin-Amgen] product name in Japan: Romiplate
		Idiopathic (Immune) Thrombocytopenic Purpura	CN						
		Aplastic Anemia Who Were Previously Untreated with Immunosuppressive Therapy	JP Asia						
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	EU						[In-House] product name in Japan: Acoalan
KHK4951		Wet Age-Related Macular Degeneration	JP						[In-House]